The safety and efficacy of vinorelbine as a single agent was evaluated in one randomized multicenter trial. Study 3 was a randomized, open-label clinical trial of vinorelbine or fluorouracil (FU) plus leucovorin (LV) in patients with Stage IV NSCLC who had not received prior chemotherapy. A total of 211 patients were randomized 2:1 to receive vinorelbine 30 mg/m2 weekly of an 8-week cycle (N=143) or FU 425 mg/m2 bolus intravenously plus LV 20 mg/m2 bolus intravenously daily for 5 days of a 4-weeks cycle (N=68).
Patient demographics and disease characteristics were in general similar between arms. In the overall population, the median age was 61 years (range 32 to 83), 74% were male, 88% were White, 46% had adenocarcinoma histology. Fifty percent of the patients had Karnofsky performance status ≥ 90 in the vinorelbine arm compared to 38% in the FU/LV arm.
The primary efficacy outcome of the study was overall survival. The median survival time was 30 weeks versus 22 weeks for patients receiving vinorelbine versus FU/LV, respectively (p=0.06). Partial objective responses were observed in 11.1% (95% CI=6.2%, 17.9%) and 3.5% (95% CI=0.4%, 11.9%) of patients who received vinorelbine and FU/LV, respectively.
- OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html
Vinorelbine Injection, USP is supplied as follows:
|Vinorelbine Injection, USP|
|NDC||(10 mg per mL)||Package Factor|
|25021-204-01||10 mg per mL Single-Dose Vial||1 vial per carton|
|25021-204-05||50 mg per 5 mL Single-Dose Vial||1 vial per carton|
Vinorelbine Injection, USP is a clear, colorless to pale yellow aqueous solution.
Store refrigerated between 2° and 8°C (36° and 46°F).
Do not freeze.
Protect from light. Retain in carton until time of use.
Discard unused portion.
Unopened vials of Vinorelbine Injection, USP are stable at 25°C (77°F) for up to 72 hours. Store diluted solutions of Vinorelbine Injection, USP at 5° to 30°C (41° to 86°F) [see Dosage and Administration (2.3)].
Vinorelbine Injection, USP is a cytotoxic drug. Follow applicable special handling and disposal procedures.1
Sterile, Nonpyrogenic, Preservative-free.
The container closure is not made with natural rubber latex.
Advise patients to contact a healthcare provider for new onset fever, or symptoms of infection [see Warnings and Precautions (5.1)].
Constipation and Bowel Obstruction
Advise patients to follow a diet rich in fibers, drink fluids to stay well hydrated and use stool softeners to avoid constipation. Contact a health care provider for severe constipation, new onset abdominal pain, nausea and vomiting [see Warnings and Precautions (5.3)].
Advise patients to contact a health care provider for new onset or worsening of numbness, tingling, decrease sensation or muscle weakness [see Warnings and Precautions (5.5)].
Advise patients to contact a healthcare provider for new onset or worsening of shortness of breath, cough, wheezing or other new pulmonary symptoms [see Warnings and Precautions (5.6)].
- Advise pregnant women of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1, 8.3)].
- Advise females of reproductive potential to use effective contraception during treatment with Vinorelbine Injection and for 6 months after the final dose [see Use in Specific Populations (8.3)].
- Advise males with female partners of reproductive potential to use effective contraception during treatment with Vinorelbine Injection and for 3 months after the final dose [see Use in Specific Populations (8.3) and Nonclinical Toxicology (13.1)].
Advise women not to breastfeed during treatment with Vinorelbine Injection and for 9 days after the final dose [see Use in Specific Populations (8.2)].
Advise males of reproductive potential that Vinorelbine Injection may impair fertility [see Use in Specific Populations (8.3)].
Mfd. for SAGENT Pharmaceuticals
Schaumburg, IL 60195 (USA)
Made in China©2020 Sagent Pharmaceuticals, Inc.
Revised: April 2020
PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
VINORELBINE INJECTION, USP
10 mg per mL
1 mL Single-Dose Vial
Must Be Diluted
For Intravenous Use Only
Caution: Cytotoxic Agent
|VINORELBINE vinorelbine injection, solution|
|Labeler — Sagent Pharmaceuticals (796852890)|
Revised: 04/2020 Sagent Pharmaceuticals
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.